Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Sequenom, Inc (NASDAQ:SQNM) rose by 6.90%. The shares opened at a price of $2.31, which touched the intraday high of $2.51 and headed to a close of $2.48. Around 3.03 million exchanged hands over the trading day and an average volume of 3.85 million shares were traded over a 30 day period. The 52-week low of Sequenom, Inc (NASDAQ:SQNM) shares is $1.65 and its 52-week high is $5.36. Sequenom, Inc (NASDAQ:SQNM) has a market capitalization of $286.98 million.
About the company
Sequenom, Inc (NASDAQ:SQNM) was formed in 1994. It is a molecular-diagnostic testing & genetics-analysis company that is committed to providing molecular-diagnostic testing services & research-use only services. In addition to this, Sequenom, Inc (NASDAQ:SQNM) has products, applications & genetic-analysis products that translate results of genomic- science into solutions that are used in biomedical research, translational-research, molecular medicine applications & livestock, agricultural & other research areas.
Sequenom, Inc (NASDAQ:SQNM)’s development & commercialization- efforts in different diagnostic areas include the noninvasive women’s-health-related & prenatal diagnostics, ophthalmology & other medical-conditions, like oncology, infectious-diseases & autoimmunity. Sequenom, Inc (NASDAQ:SQNM) operates in 2 business segments: Molecular Diagnostics. This includes its Sequenom Center for Molecular-Medicine, LLC/ Sequenom CMM) & Genetic Analysis. In 2011 November, Sequenom, Inc (NASDAQ:SQNM) entered into leases for additional-laboratory & office-space in California, San Diego and Durham, North Carolina.
Sequenom, Inc (NASDAQ:SQNM) is involved in researching & developing & pursuing commercialization of different noninvasive molecular-diagnostic tests for prenatal-genetic disorders & diseases, women’s-health-related disorders & diseases, ophthalmology & other medical-conditions like infectious diseases oncology & autoimmunity. As of 31 December 2011, Sequenom, Inc (NASDAQ:SQNM) is mainly focused on developing & commercializing prenatal-diagnostic tests. All these test use the company’s patent-protected, foundational, non-invasive, circulating cell-free fetal , nucleic-acid-based assay technology, which Sequenom, Inc (NASDAQ:SQNM) had in-licensed from the Isis Innovation Limited.